InvestorsHub Logo
Followers 840
Posts 121043
Boards Moderated 9
Alias Born 09/05/2002

Re: DewDiligence post# 1025

Tuesday, 07/11/2023 12:30:51 PM

Tuesday, July 11, 2023 12:30:51 PM

Post# of 1170
Opdivo monotherapy—>statsig OS/PFS as_addend_to_cisplatin_in first-line bladder cancer:

https://finance.yahoo.com/news/opdivo-nivolumab-combination-cisplatin-based-105900450.html

The trial in question is a 600-patient sub-study of CHECKMATE-901, which is now complete. (The other part of CHECKMATE-901, which compares Opdivo/Yervoy vs chemo, is ongoing.) The trial had no requirement for PD-L1 expression.

Today’s PR does not contain a hazard ratio or any other detailed results; those data will be presented at an unspecified medical conference.

Opdivo for bladder cancer is already FDA-approved in the adjuvant (#msg-165546303) and second-line (#msg-128386168) settings. Approval in the first-line (unresectable or metastatic) setting would give Opdivo across-the-board coverage for bladder cancer.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

57.051
0.011 (0.02%)
Volume: 8,104,674
Day Range: 56.29 - 57.39
Bid:
Ask:
Last Trade Time: 7:59:30 PM EST
Total Trades: 72,970
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BMY News